Fish Oil (Omega 3 ) in Sjogren's Syndrome

NCT05005806 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-02-28

No results posted yet for this study

Summary

Sjögren's syndrome (pSS) is an autoimmune disorder affecting mainly the exocrine glands.this lead to dryness of the main mucosal surface ,such as the mouth ,eye,skin nose,pharynx,larynx and vagina . The history of the disease is characterized by a slowly progression of sicca symptoms and fatigue; however, a subset of patients would experience extra glandular activity. Lipid mediators derived from polyunsaturated fatty acids, related to inflammation and immune response regulation. In this sense, the polyunsaturated fatty acids omega-3 (ω-3 FA) have been associated with several illnesses such as cancer, cardiovascular disease and autoimmune diseases and their balance at the cellular membranes can result in an anti-inflammatory .

Conditions

  • Sjogren's Syndrome

Interventions

DRUG

Omega 3 fatty acid

omega 3 fatty acid soft gel

DRUG

Placebo

placebo soft gel

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Ziad SH AL Rawi, F R C P London · Professor of Rheumatolgy,Baghdad University

  • Aryan MF Jalal, M.B.CH.B · Rheumatology,Hawler medical uiversity,Kurdistan Board for medical specialities

  • Ibtihal HH Faraj, M-B.CH.B · Rheumatology,Hawler medical university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-02
Primary Completion
2023-02-01
Completion
2023-02-07

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05005806 on ClinicalTrials.gov